アキュルナ株式会社 (Accurna)
acquired by NanoCarrier2 known investors
Find your way into アキュルナ株式会社 (Accurna)
AccuRna develops drug delivery systems for nucleic acid therapeutics, including antisense oligonucleotides, siRNA, miRNA, and mRNA-based treatments. The company focuses on enabling the development of novel medicines for refractory diseases with no current cure.
Founders & leadership
SA
Shiro AkinagaChairman of the board, CEO
KH
Keiko HattoriDirector, CEO
MT
Makoto TakeuchiCorporate Auditor
Board
KK
Kazunori KataokaProject Professor of Policy Alternatives Research Institute at the University of Tokyo, Director General at Innovation Center of NanoMedicine
KI
Keiji ItakaProfessor of Institute of Biomaterials and Bioengineering at Tokyo Medical and Dental University, Principal Research Scientist and Laboratory Head at Innovation Center of NanoMedicine
NN
Nobuhiro NishiyamaProfessor of Laboratory for Chemistry and Life Science at Tokyo Institute of Technology, Principal Research Scientist and Laboratory Head at Innovation Center of NanoMedicine
KM
Kanjiro MiyataAssociate Professor of Department of Materials Engineering at the University of Tokyo
HK
Hiromichi KimuraBoard director
TA
Tomohiro AnzaiBoard director
MK
Mikio KawaharaBoard director
Investors · 2
Frequently asked questions
- What does アキュルナ株式会社 (Accurna) do?
- AccuRna develops drug delivery systems for nucleic acid therapeutics, including antisense oligonucleotides, siRNA, miRNA, and mRNA-based treatments. The company focuses on enabling the development of novel medicines for refractory diseases with no current cure.
- Who are アキュルナ株式会社 (Accurna)'s investors?
- アキュルナ株式会社 (Accurna)'s investors include Fast Track Initiative, UTokyo Innovation Platform Co. Ltd..
- Who acquired アキュルナ株式会社 (Accurna)?
- アキュルナ株式会社 (Accurna) was acquired by NanoCarrier.